MedTrace Logo

Thromboxane Receptor Antagonist to Improve Endothelial Function

NCT03962855 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2024-12-05

Study results available
· View outcomes & findings →

Summary

This study evaluates whether addition of the thromboxane receptor antagonist to chronic aspirin therapy improves endothelial function and reduces non-platelet thromboxane generation in patients with established cardiovascular disease. Half of participants will receive ifetroban and the other half will receive matching placebo for the 4 week study period.

Conditions

Interventions

DRUG

Ifetroban Sodium

Ifetroban sodium 250 mg capsule once daily for 4 weeks

DRUG

Placebo

Placebo arm to match Ifetroban Sodium once daily for 4 weeks.

Sponsors & Collaborators

Principal Investigators

  • Jeffrey J Rade, MD · University of Massachusetts, Worcester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-20
Primary Completion
2022-11-07
Completion
2022-11-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03962855 on ClinicalTrials.gov